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ABSTRACT
Despite recent large-scale profiling efforts, the best prognostic predictor of 
glioblastoma multiforme (GBM) remains the patient’s age at diagnosis. We 
describe a global pattern of tumor-exclusive co-occurring copy-number 
alterations (CNAs) that is correlated, possibly coordinated with GBM patients’ 
survival and response to chemotherapy. The pattern is revealed by generalized 
singular value decomposition (GSVD) comparison of patient-matched but probe- 
independent GBM and normal aCGH datasets from The Cancer Genome Atlas 
(TCGA). We find that, first, the GSVD, formulated as a framework for 
comparatively modeling two composite datasets, removes from the pattern copy- 
number variations (CNVs) that occur in the normal human genome (e.g., female- 
specific X chromosome amplification) and experimental variations (e.g., in tissue 
batch, genomic center, hybridization date and scanner), without a-priori 
knowledge of these variations. Second, the pattern includes most known GBM- 
associated changes in chromosome numbers and focal CNAs, as well as several 
previously unreported CNAs in > 3% of the patients. These included the 
biochemically putative drug target, cell cycle-regulated serine/threonine kinase- 
encoding TLK2, the cyclin El-encoding CCNE1, and the Rb-binding histone 
demethylase-encoding KDM5A. Third, the pattern provides a better prognostic
predictor than the chromosome numbers or any one focal CNA that it identifies, 
suggesting that the GBM survival phenotype is an outcome of its global 
genotype. The pattern is independent of age, and combined with age, makes a 
better predictor than age alone. GSVD comparison of matched profiles of a larger 
set of TCGA patients, inclusive of the initial set, confirms the global pattern. 
GSVD classification of the GBM profiles of an independent set of patients 
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Abstract
Despite recent large-scale profiling efforts, the best prognostic predictor of glioblastoma multiforme (GBM) remains the 
patient's age at diagnosis. We describe a global pattern of tumor-exclusive co-occurring copy-number alterations (CNAs) 
that is correlated, possibly coordinated with GBM patients' survival and response to chemotherapy. The pattern is revealed 
by GSVD comparison of patient-matched but probe-independent GBM and normal aCGH datasets from The Cancer Genome 
Atlas (TCGA). We find that, first, the GSVD, formulated as a framework for comparatively modeling two composite datasets, 
removes from the pattern copy-number variations (CNVs) that occur in the normal human genome (e.g., female-specific X 
chromosome amplification) and experimental variations (e.g., in tissue batch, genomic center, hybridization date and 
scanner), without a-priori knowledge of these variations. Second, the pattern includes most known GBM-associated changes 
in chromosome numbers and focal CNAs, as well as several previously unreported CNAs in > 3 %  of the patients. These 
include the biochemically putative drug target, cell cycle-regulated serine/threonine kinase-encoding TLK2, the cyclin E1- 
encoding CCNE1, and the Rb-binding histone demethylase-encoding KDM5A. Third, the pattern provides a better prognostic 
predictor than the chromosome numbers or any one focal CNA that it identifies, suggesting that the GBM survival 
phenotype is an outcome of its global genotype. The pattern is independent of age, and combined with age, makes a better 
predictor than age alone. GSVD comparison of matched profiles of a larger set of TCGA patients, inclusive of the initial set, 
confirms the global pattern. GSVD classification of the GBM profiles of an independent set of patients validates the 
prognostic contribution of the pattern.
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Introduction
Glioblastoma multiforme (GBM), the most com m on brain 
tum or in adults, is characterized by poor prognosis [1]. GBM 
tumors exhibit a range o f copy-num ber alterations (CNAs), many 
o f which play roles in the cancer’s pathogenesis [2—4]. Recent 
large-scale gene expression [5—7] and DNA m ethylation [8] 
profiling efforts identified GBM  molecular subtypes, distinguished 
by small numbers of biomarkers. However, despite these efforts, 
GBM ’s best prognostic predictor remains the patient’s age at 
diagnosis [9,10].
T o  identify CNAs that might predict GBM  patients’ survival, 
we comparatively model patient-m atched GBM and norm al array 
C G H  (aCGH) profiles from The C ancer Genome Atlas (TCGA) 
by using the generalized singular value decomposition (GSVD) 
[11]. Previously, we formulated the GSVD as a framework for 
comparatively modeling two composite datasets [12] (see also
[13]), and illustrated its application in sequence-independent 
com parison of D NA m icroarray data from two organisms, where,
as we showed, the mathem atical variables and operations o f the 
GSVD represent experim ental or biological reality. T he variables, 
subspaces of significant patterns that are uncovered in the 
simultaneous decomposition o f the two datasets and are 
mathematically significant in either both  (i.e., com m on to both) 
datasets or only one (i.e., exclusive to one) o fth e  datasets, correlate 
with cellular programs that are either conserved in both  or unique 
to only one o f the organisms, respectively. The operation of 
reconstruction in the subspaces that are mathematically common 
to both  datasets outlines the biological similarity in the regulation 
o f the cellular programs that are conserved across the species. 
Reconstruction in the com m on and exclusive subspaces o f either 
dataset outlines the differential regulation o f the conserved relative 
to the unique programs in the corresponding organism.
W e now find that also in probe-independent com parison of 
aC G H  data from  patient-m atched tum or and  norm al samples, the 
m athem atical variables o f the GSVD, i.e., shared tum or and 
norm al patterns of copy-num ber variation across the patients and 
the corresponding tum or- and normal-specific patterns o f copy-
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num ber variation across the tum or and norm al probes, represent 
experimental or biological reality. Patterns that are m athem ati­
cally significant in both  datasets represent copy-number variations 
(CNVs) in the norm al hum an genome that are conserved in the 
tum or genome (e.g., female-specific X  chromosome amplification). 
Patterns that are mathematically significant in the norm al but not 
the tum or dataset represent experimental variations that exclu­
sively affect the norm al dataset. Similarly, some patterns that are 
mathematically significant in the tum or but not the norm al dataset 
represent experimental variations that exclusively affect the tum or 
dataset.
O ne  pattern, that is mathematically significant in the tum or but 
not the norm al dataset, represents tumor-exclusive co-occurring 
CNAs, including most known GBM -associated changes in 
chromosome num bers and focal CNAs, as well as several 
previously unreported CNAs in > 3 %  of the patients [14]. This 
pattern  is correlated, possibly coordinated with GBM patients’ 
survival and response to therapy. W e find that the pattern  provides 
a prognostic predictor that is better than the chromosome 
numbers or any one focal CNA that it identifies, suggesting that 
the GBM survival phenotype is an  outcome of its global genotype. 
T he pattern  is independent of age, and  combined with age, makes 
a better predictor than age alone.
W e confirm our results with GSVD comparison of matched 
profiles o f a larger set of TC G A  patients, inclusive of the initial set. 
W e validate the prognostic contribution of the pattern  with GSVD 
classification of the GBM  profiles of a set of patients that is 
independent o f both the initial set and the inclusive confirmation 
set [15].
Methods
To com pare T C G A  patient-m atched GBM and  norm al (mostly 
blood) aC G H  profiles (Dataset S1 and M athem atica Notebooks S1 
and S2), Agilent H um an aC G H  244A-measured 365 tum or and 
360 norm al profiles were selected, corresponding to the same 
N  = 251 patients. Each profile lists log2 o f the T C G A  level 1 
background-subtracted intensity in the sample relative to the 
Prom ega DNA reference, with signal to background > 2 .5  for 
both  the sample and reference in more than 90% o f the 223,603 
autosomal probes on the microarray. The profiles are organized in 
one tum or and one norm al dataset, of M i  =212,696 and 
M 2 = 211,227 autosomal and X  chromosome probes, each probe 
with valid data in a t least 99% o f either the tum or or normal 
arrays, respectively. Each profile is centered a t its autosomal 
m edian copy num ber. The < 0 .2%  missing data entries in the 
tum or and  norm al datasets are estimated by using singular value 
decomposition (SVD) as described [12,16]. W ithin each set, the 
medians o f profiles o f samples from the same patient are taken.
The structure o f the patient-m atched bu t probe-independent 
tum or and norm al datasets D i and D 2 , o f N  patients, i.e., N- 
arrays x M i-tum or and M 2-norm al probes, is o f an  order higher 
than that o f a single matrix. The patients, the tum or and  normal 
probes as well as the tissue types, each represent a degree of 
freedom. Unfolded into a single matrix, some o f the degrees of 
freedom are lost and m uch ofthe  information in the datasets might 
also be lost.
To compare the tum or and norm al datasets, therefore, we use 
the GSVD, form ulated to simultaneously separate the paired 
datasets into paired weighted sums o f N  outer products of two 
patterns each: O ne pattern  of copy-number variation across the 
patients, i.e., a “probelet” vj , which is identical for both the tum or 
and norm al datasets, combined with either the corresponding 
tumor-specific pattern  o f copy-number variation across the tum or
probes, i.e., the ‘‘tum or arraylet’’ Ui>n, or the corresponding 
normal-specific pattern  across the norm al probes, i.e., the ‘‘norm al 
arraylet’’ U2,n (Figure 1),
N
D i = U iS i V T = Si,nUi,n®vJ,
n= 1
N
D 2 =  U2S 2 V T = ^ 2  S2,nU2,n®VT . (i)
n= i
T he probelets are, in general, non-orthonorm al, but are 
normalized, such that vj vn =  i.  The tum or and norm al arraylets 
are orthonorm al, such that Uj  Ui = Uj  U2 =  I .
The significance of the probelet vnT in either the tum or or 
norm al dataset, in terms of the overall information that it captures 
in this dataset, is proportional to either o f the weights si,n or S2,n, 
respectively (Figure S1 in Appendix S1),
Pi,n =  s i n /  X
n= i
N
p 2,n =  S 2,n/  s2,n' (2)
n= i
T he ‘‘generalized norm alized Shannon entropy’’ o f each dataset,
N
0 <  di =  (log N ) { i ^ 2 P i ,n log p i ,n<  i,
n= i
N
0 < d2 =  (log N ) { i ^ P 2,n lo g P 2,n < i ,  (3)
n= i
measures the complexity o f the data from the distribution o f the 
overall information am ong the different probelets and  correspond­
ing arraylets. An entropy o f zero corresponds to an  ordered and 
redundant dataset in which all the information is captured by a 
single probelet and its corresponding arraylet. An entropy of one 
corresponds to a disordered and random  dataset in which all 
probelets and arraylets are of equal significance. The significance 
o f the probelet vj  in the tum or dataset relative to its significance in 
the norm al dataset is defined in terms of an  ‘‘angular distance’’ hn 
that is proportional to the ratio o f these weights,
— p /4  <  hn =  arctan(si,n  /  s2,n) — p / 4 < p / 4 .  (4)
An angular distance of +  p /4  indicates a probelet that is exclusive 
to either the tum or or norm al dataset, respectively, whereas an 
angular distance o f zero indicates a probelet that is common to 
both  the tum or and norm al datasets. The probelets are arranged 
in decreasing order of their angular distances, i.e., their 
significance in the tum or dataset relative to the norm al dataset.
We find that the two most tumor-exclusive mathem atical 
patterns ofcopy-num ber variation across the patients, i.e., the first 
probelet (Figure S2 in Appendix S1) and the second probelet 
(Figure 2 a-c), with angular distances > 2 p /9 ,  are also the two 
most significant probelets in the tum or dataset, with *  11% and
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Arrays A rra y le ts  P robe le ts  Arrays
Figure 1. G eneralized  singular v a lu e  decom position  (GSVD) o f th e  TCGA patien t-m atch ed  tu m o r and norm al aCGH profiles . The
structure o f the patient-m atched but probe-independent tum o r and normal datasets D i and D 2, o f the initial set o f N  = 251 patients, i.e., N-arrays x 
M\ =212,696-tum or probes and M 2 = 211,227-normal probes, is o f an order higher than that o f a single matrix. The patients, the tum or and normal 
probes as well as the tissue types, each represent a degree o f freedom . Unfolded in to a single matrix, some o f the degrees o f freedom are lost and 
much o f th e  in form ation in the datasets m ight also be lost.The GSVD simultaneously separates the paired datasets in to paired weighted sums o f N  
outer products o f tw o  patterns each: One pattern o f copy-num ber variation across the patients, i.e., a ''p robe le t" v j,  which is identical fo r both the 
tum or and normal datasets, com bined w ith  either the corresponding tumor-specific pattern o f copy-num ber variation across the tum or probes, i.e., 
the ''tum o r arraylet'' wi,„, or the corresponding normal-specific pattern across the normal probes, i.e., the ''norm al arraylet'' «2,n (Equation 1). This is 
depicted in a raster display, w ith  relative copy-num ber gain (red), no change (black) and loss (green), explicitly showing only the first though the 10th 
and the 242nd through the 251st probelets and corresponding tum or and normal arraylets, which capture *5 2 %  and 71% o f the in form ation in the 
tum or and normal dataset, respectively. The significance o f th e  probelet v j  in the tum or dataset relative to  its significance in the normal dataset is 
defined in terms o f an ''angular distance'' that is proportional to  the ratio o f these weights (Equation 4). This is depicted in a bar chart display, 
showing that th e firs t and second probelets are almost exclusive to  the tum orda taset w ith  angulardistances > 2 p /9 , the 247th to  251st probelets are 
approximately exclusive to the normal dataset w ith  angular distances v  — p /6 , and the 246th probelet is relatively com m on to  the normal and tum or 
datasets w ith  an angular distance >  — p/6. We find  and confirm  that the second most tumor-exclusive probelet, which is also the most significant 
probelet in the tum or dataset, significantly correlates w ith  GBM prognosis. The corresponding tum or arraylet describes a global pattern o f tum or- 
exclusive co-occurring CNAs, including most known GBM-associated changes in chromosome numbers and focal CNAs, as well as several previously 
unreported CNAs, including the biochemically putative drug target-encoding TLK2 [22-25]. We find  and validate that a neglig ible w e ight o f the 
global pattern in a patient's GBM aCGH profile is indicative o f a significantly longer GBM survival tim e. It was shown that the GSVD provides a 
mathematical fram ework fo r comparative m odeling o f DNA m icroarray data from  tw o  organisms [12,39]. Recent experimental results [40] verify a 
com putationally predicted genom e-w ide m ode o f regulation [41,42], and dem onstrate that GSVD modeling o f DNA microarray data can be used to 
correctly predict previously unknown cellular mechanisms. This GSVD comparative m odeling ofaCGH data from  patient-m atched tu m o ra n d  normal 
samples, therefore, draws a mathematical analogy between the prediction o f cellular modes o f regulation and the prognosis o f cancers. 
doi:10.1371/journal.pone.0030098.g001
22% of the information in this dataset, respectively. Similarly, the 
five most normal-exclusive probelets, the 247th to 251st probelets 
(Figures S3, S4, S5, S6, S7 in A ppendix S1), with angular distances 
v — p /6 , are am ong the seven most significant probelets in the 
norm al dataset, capturing together * 5 6 %  of the inform ation in 
this dataset. The 246th probelet (Figure 2 d—f), which is the second 
most significant probelet in the norm al dataset with * 8 %  of the 
information, is relatively com m on to the norm al and tum or 
datasets with an  angular distance > — p /6 .
T o  biologically or experimentally interpret these significant 
probelets, we correlate or anticorrelate each probelet with relative 
copy-num ber gain or loss across a group o f patients according to 
the TC G A  annotations o f the group o f n  patients with largest or 
smallest relative copy num bers in this probelet am ong all N  
patients, respectively. T he P-value o f a given association is 
calculated assuming hypergeometric probability distribution of 
the K  annotations am ong the N  patients, and of the subset of 
k ( K  annotations am ong the subset o f n patients, as described
PLoS ONE | www.plosone.org January 2012 | Volum e 7 | Issue 1 | e300983
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Figure 2. S ign ifican t p robe lets  and corresponding tu m o r and norm al arraylets  uncovered by G SVD o f th e  patien t-m atch ed  GBM  
and norm al aCGH profiles . (a) Plot o fth e  second tum or arraylet describes a global pattern oftum or-exclusive co-occurring CNAs across the tum or 
probes. The probes are ordered, and the ir copy numbers are colored, according to each probe's chromosomal location. Segments (black lines) 
identified by circular binary segm entation (CBS) [20,21] include most known GBM-associated focal CNAs (black), e.g., EGFR am plification. CNAs 
previously unrecognized in GBM (red) include an am plification o f a segment containing the biochem ically putative drug target-encoding TLK2. (b) 
Plot o f the second most tumor-exclusive probelet, which is also the most significant probelet in the tum or dataset (Figure S1a in Appendix S1), 
describes the corresponding variation across the patients. The patients are ordered and classified according to each patient's relative copy num ber in 
this probelet. There are 227 patients (blue) w ith  high (>0.02) and 23 patients (red) w ith  low, approximately zero, numbers in the second probelet. 
One patient (gray) remains unclassified w ith  a large negative ( < —0.02) number. This classification significantly correlates w ith  GBM survival times 
(Figure 3a and Table S1 in Appendix S1). (c) Raster display o f the tum o r dataset, w ith  relative gain (red), no change (black) and loss (green) o f DNA 
copy numbers, shows the correspondence between the GBM profiles and the second probelet and tum o r arraylet. Chromosome 7 gain and losses of 
chromosomes 9p and 10, which are dom inant in the second tum or arraylet (Figure 2a), are neglig ible in the patients w ith  low copy numbers in the 
second probelet, but distinct in the remaining patients (Figure 2b). This illustrates that the copy numbers listed in the second probelet correspond to 
the weights o f the second tum or arraylet in the GBM profiles o f the patients. (d) Plot o f the 246th normal arraylet describes an X chromosome- 
exclusive am plification across the normal probes. (e) Plot o f the 246th probelet, which is approxim ately com m on to both  the normal and tum or 
datasets, and is the second most significant in the normal dataset (Figure S1 b in Appendix S1), describes the corresponding copy-num ber 
am plification in the female (red) relative to  the male (blue) patients. Classification o fth e  patients by the 246th probelet agrees w ith  the copy-number 
gender assignments (Table 1 and Figure S9 in Appendix S1), also fo r three patients w ith  missing TCGA gender annotations and three additional 
patients w ith  conflicting TCGA annotations and copy-num ber gender assignments. (f) Raster display o f the normal dataset shows the correspondence 
between the normal profiles and the 246th probelet and normal arraylet. X chromosom e am plification, which is dom inant in the 246th normal 
arraylet (Figure 2d), is distinct in the female bu t nonexisting in the male patients (Figure 2e). Note also that although the tum or samples exhibit 
female-specific X chromosome am plification (Figure 2c), the second tum or arraylet (Figure 2a) exhibits an unsegmented X chromosome copy- 
num ber d istribu tion, that is approximately centered at zero w ith  a relatively small w idth. 
doi:10.1371/journal.pone.0030098.g002
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6[17], P(k; n ,N  ,f ) =  ( f  ) En=k( f) ( "  ) C ^ e  1).
W e visualize the copy-num ber distribution between the annota­
tions that are associated with largest or smallest relative copy 
num bers in each probelet by using boxplots, and by calculating the 
corresponding M ann-W hitney-W ilcoxon P-value (Figures S8 and 
S9 in Appendix S1). T o  interpret the corresponding tum or and 
norm al arraylets, we m ap the tum or and norm al probes onto the 
N ational C enter for Biotechnology Inform ation (NCBI) hum an 
genome sequence build 36, by using the Agilent Technologies 
probe annotations posted at the University of California at Santa 
C ruz (UCSC) hum an genome browser [18,19]. W e segment each 
arraylet and assign each segment a P-value by using the circular 
binary segmentation (CBS) algorithm as described (Dataset S2) 
[20,21]. W e find that the significant probelets and corresponding 
tum or and norm al arraylets, as well as their interpretations, are 
robust to variations in the preprocessing o f the data, e.g., in the 
data selection cutoffs.
Results
We find that, first, the GSVD identifies significant experimental 
variations that exclusively affect either the tum or or the normal 
dataset, as well as CNVs that occur in the norm al hum an genome 
and  are com m on to both datasets, w ithout a-priori knowledge of 
these variations. The mathematically most tumor-exclusive 
probelet, i.e., the first probelet (Figure S2 in Appendix S1), 
correlates with tumor-exclusive experimental variation in the 
genomic center where the GBM  samples were hybridized at, with 
the P-values < 1 0 -5  (Table 1 and  Figure S8 in Appendix S1). 
Similarly, the five most normal-exclusive probelets, i.e., the 247th 
to 251st probelets (Figures S3, S4, S5, S6, S7 in Appendix S1), 
correlate with experimental variations am ong the norm al samples 
in genomic center, DNA m icroarray hybridization or scan date as 
well as the tissue batch and hybridization scanner, with P-values
<  10- 3 . Consistently, the corresponding arraylets, i.e., the first 
tum or arraylet and  the 247th to 251st norm al arraylets, describe 
copy-num ber distributions which are approximately centered at 
zero with relatively large, chrom osom e-invariant widths.
The 246th probelet (Figure 2e), which is mathematically 
approximately com m on to both the norm al and tum or datasets, 
describes copy-num ber amplification in the female relative to the 
male patients that is biologically com m on to both  the norm al and 
tum or datasets. Consistently, both the 246th norm al arraylet 
(Figure 2d) and  246th tum or arraylet describe an X  chromosome- 
exclusive amplification. T he P-values are < 1 0 -38 (Table 1 and 
Figure S9 in Appendix S1). To assign the patients gender, we 
calculate for each patient the standard deviation o f the m ean X  
chromosome num ber from the autosom al genomic m ean in the 
patien t’s norm al profile (Figure 2 f ). Patients with X  chromosome 
amplification greater than  twice the standard deviation are 
assigned the female gender. For three of the patients, this copy- 
num ber gender assignment conflicts with the T C G A  gender 
annotation. For three additional patients, the T C G A  gender 
annotation is missing. In  all these cases, the classification of the 
patients by the 246th probelet agrees with the copy-number 
assignment.
Second, we find that the GSVD identifies a global pattern  of 
tumor-exclusive co-occurring CNAs that includes most known 
GBM-associated changes in chromosome numbers and  focal 
CNAs. This global pattern  is described by the second tum or 
arraylet (Figure 2a and Dataset S3). The second most tumor- 
exclusive probelet (Figure 2b), which describes the corresponding 
copy-num ber variation across the patients, is the most significant 
probelet in the tum or dataset. D om inant in the global pattern, and 
frequently observed in GBM  samples [2], is a co-occurrence o f a 
gain of chromosome 7 and  losses of chromosome 10 and  the short 
a rm  of chromosome 9 (9p). To assign a chromosome gain or loss, 
we calculate for each tum or profile the standard deviation of the 
m ean chromosome num ber from the autosom al genomic mean, 
excluding the outlying chromosomes 7, 9p and 10. T he gain of 
chromosome 7 and the losses of chromosomes 10 and 9p are 
greater than twice the standard deviation in the global pattern  as 
well as the tum or profiles of *  20%, 41% and  12% of the patients, 
respectively.
Focal CNAs that are known to play roles in the origination and 
development of GBM  and  are described by the global pattern
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Table 1. Enrichment of the significant probelets in TCGA annotations.
R elative D N A  C o p y  N um ber G ain R elative D N A  C o p y  N um ber Loss
P robele t Phen o typ e A n n o tatio n  n K k P-value A nnotatio n n K k P-value
1 TumorSample HMS 183 34 34 8 .5 x 1 0 -6  MSKCC 68 103 55 3 .9 x 1 0 -15
Center
246 Patient Female 86 86 84 8.0 x  10-62 Male 165 165 163 8.0 x  10-62
Gender
247 NormalSample 10.8.2009 51 6 6 5 .5 x 1 0 -5  7.22.2009 38 11 10 2 .0 x 1 0 -8
Scan Date
248 Normal Sample 
Batch/Scanner
HMS 8/2331 19 19 19 6.2 x  10-29 - - - - -
249 Normal Sample 
Batch/Scanner
- - - - - HMS 8/2331 22 19 19 9.6 x  10-26
250 Normal Sample 
Scan Date
4.18.2007 26 9 9 3.3 x  10-10 7.22.2009 25 11 9 1.1 x  10-8
Normal Sample 
Center
Probabilistic significance o f the enrichment o f the n patients, w ith  largest or smallest relative copy numbers in each significant probelet, in the respective TCGA 
annotations. The P-value o f each enrichment is calculated assuming hypergeometric probability distribution o f the f  annotations among the N  = 251 patients o f the
initial set, and o f the subset o f k ( f  annotations among the subset o f n patients, as described [17], P(k; n ,N , f ) =  ( N  ^ J2i=k( f  )  ( N  f  ) .  
doi:10.1371/journal.pone.0030098.t001 n i~k i  n { i
t||). PLoS ONE | www.plosone.org 5 January 2012 | Volum e 7 | Issue 1 | e30098
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include amplifications of segments containing the genes M D M 4  
(1q32.1), AKT3  (1q44), EGFR (7p11.2), M E T  (7q31.2), CDK4 
(12q14.1) and  M D M 2  (12q15), and deletions of segments 
containing the genes CDKN2A/B (9p21.3) and P T E N  (10q23.31), 
that occur in > 3 %  o f the patients. T o  assign a CNA in a segment, 
we calculate for each tum or profile the m ean segment copy 
num ber. Profiles with segment amplification or deletion greater 
than  twice the standard deviation from the autosomal genomic 
mean, excluding the outlying chromosomes 7, 9p and 10, or 
greater than  one standard deviation from the chromosomal mean, 
w hen this deviation is consistent with the deviation from the 
genomic mean, are assigned a segment gain or loss, respectively. 
T he frequencies of amplification or deletion we observe for these 
segments are similar to the reported  frequencies of the corre­
sponding focal CNAs [4].
Novel CNAs, previously unrecognized in GBM, are also 
revealed by the global pattern  [14]. These include an amplification 
o f a segment that contains TLK2 (17q23.2) in * 2 2 %  of the 
patients, with the corresponding CBS P-value <  10_ 140. Copy- 
num ber amplification o f TLK2 has been correlated with 
overexpression in several other cancers [22,23]. The hum an gene 
TLK2, with homologs in the plant Arabidopsis thaliana bu t not in the 
yeast Saccharomyces cerevisiae, encodes for a multicellular organisms- 
specific serine/threonine protein kinase, a biochemically putative 
drug target [24], which activity is directly dependent on ongoing 
D N A  replication [25]. O n  the same segment with TLK2, we also 
find the gene M E TTL2A. Another amplified segment (CBS P- 
value <  10-13) contains the homologous gene M E T T L 2B  (7q32.1). 
Overexpression o f M E T T L 2 A /B  was linked with prostate cancer 
metastasis [26], cAMP response element-binding (CREB) regula­
tion in myeloid leukemia [27], and breast cancer patients’ response 
to chem otherapy [28].
An amplification of a segment (CBS P-value <  10_ 145) encom ­
passing the cyclin E1-encoding CCNE1 (19q12) is revealed in 
* 4 %  of the patients. Cyclin E1 regulates entry into the DNA 
synthesis phase o fthe  cell division cycle. Copy num ber increases of 
CCNE1 have been linked with multiple cancers [29,30], but not 
GBM. Amplicon-dependent expression of CCNE1, together with 
the genes POP4, PLEKHF1, C19orf12 and C19orf2 that flank 
CCNE1 on this segment, was linked with prim ary treatm ent failure 
in ovarian cancer, possibly due to rapid repopulation o f the tumor 
after chem otherapy [31].
A nother rare amplification in * 4 %  o f the patients, o f a 
segm ent (CBS P-value <  10-28) that overlaps with the 5 ' end of 
KDM5A (12p 13.33), is also revealed. T he pro tein  encoded by 
KDM5A, a retinoblastom a tum or suppressor (Rb)-binding lysine- 
specific histone demethylase [32], has been  recently implicated 
in cancer drug tolerance [33]. T he same amplified segment 
includes the solute carrier (SLC) sodium -neurotransm itter 
symporters SL C 6A 12/13, biochemically putative carriers of 
drugs that m ight overcome the blood-brain barrie r [34]. O n 
the same segm ent we also find IQSEC3 , a m ature neuron- 
specific guanine nucleotide exchange factor (GEF) for the ADP- 
ribosylation factor (ARF) ARF1, a key regulator o f intracellular 
m em brane traffic [35].
Note that although the tum or samples exhibit female-specific X  
chromosome amplification (Figure 2c), the second tum or arraylet 
exhibits an  unsegmented X  chromosome copy-number distribu­
tion, that is approximately centered a t zero with a relatively small 
width. This illustrates the m athem atical separation of the global 
pattern  o f tumor-exclusive co-occurring CNAs, that is described 
by the second tum or arraylet, from all other biological and 
experimental variations that compose either the tum or or the 
norm al dataset, such as the gender variation that is com m on to
both datasets, and is described by the 246th probelet and  the 
corresponding 246th tum or and 246th norm al arraylets.
Third, we find that the GSVD classifies the patients into two 
groups o f significantly different prognoses. T he classification is 
according to the copy num bers listed in the second probelet, which 
correspond to the weights o f the second tum or arraylet in the 
GBM aC G H  profiles of the patients. A group o f 227 patients, 224 
of which with T C G A  annotations, displays high (> 0 .02) relative 
copy numbers in the second probelet, and  a K aplan-M eier (KM) 
[36] median survival time o f *  13 months (Figure 3a). A group of 
23 patients, i.e., *  10% o f the patients, displays low, approxi­
mately zero, relative copy numbers in the second probelet, and a 
K M  m edian survival time o f *  29 months, which is more than 
twice longer than  that o f the previous group. The corresponding 
log-rank test P-value is < 1 0 _3. T he univariate Cox [37] 
proportional hazard ratio is 2.3, with a P-value <  10_ 2 (Table 
S1 in Appendix S1), meaning that high relative copy numbers in 
the second probelet confer more than twice the hazard of low 
numbers. Note that the cutoff o f +  0.02 was selected to enable 
classification o f as m any o f the patients as possible. Only one o f the 
251 patients has a negative copy num ber in the second probelet
<  —0.02, and remains unclassified. This patient is also missing the 
TC G A  annotations. Survival analysis o f only the chem otherapy 
patients classified by GSVD gives similar results (Table S2 and 
Figure S10a in Appendix S1). T he P-values are calculated without 
adjusting for multiple comparisons [38]. W e observe, therefore, 
that a negligible weight o f the global pattern  in a patient’s GBM 
aC G H  profile is indicative o f a significantly longer survival time, as 
well as an improved response to treatm ent am ong chem otherapy 
patients.
A m utation in the gene IDH1 was recently linked with improved 
GBM prognosis [1,6] and associated with a C pG  island m ethylator 
phenotype [8]. W e find, however, only seven patients (six 
chm eotherapy patients), i.e., < 3 % , with IDH1 mutation. This is 
less than a third of the 23 patients in the long-term survival group 
defined by the global pattern. T he corresponding survival analyses 
are, therefore, statistically insignificant (Figures S11 and S12 in 
A ppendix S1).
Chrom osom e 10 loss, chromosome 7 gain and even loss of 9p, 
which are dom inant in the global pattern, have been suggested as 
indicators o f poorer GBM prognoses for over two decades [2,3]. 
However, the K M  survival curves for the groups o f patients with 
either one of these chromosome num ber changes almost overlap 
the curves for the patients with no changes (Figure S13 in 
A ppendix S1). The log-rank test P-values for all three classifica­
tions are > 10_1, with the m edian survival time differences *3 
months. Similarly, in the K M  survival analyses o f the groups of 
patients with either a CNA or no CNA in either one o f the 130 
segments identified by the global pattern  (Figure S14 in Appendix 
S1), log-rank test P-values <  5 x  10_2 are calculated for only 12 of 
the classifications. O fthese , only six correspond to a K M  median 
survival time difference that is *> 5 m onths, approxim ately a 
third o f the *  16 months difference observed for the GSVD 
classification.
One o f these segments contains the genes TLK2 and M E TTL2A  
and another segment contains the homologous gene M E T T L 2B , 
previously unrecognized in GBM. T he K M  m edian survival times 
we calculate for the 56 patients with TLK2/M ETTL2A  amplifi­
cation and, separately, for the 19 patients with M E T T L 2B  
amplifications are *  5 and 8 months longer than that for the 
rem aining patients in each case. Similarly, the K M  median 
survival times we calculate for the 43 chem otherapy patients with 
TLK 2/M ETTL2A  amplification and, separately, for the 15 
chem otherapy patients with M E T T L 2B  amplification, are both
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Figure 3 . Survival analyses o f th e  th ree  sets o f p atien ts  classified b y  G SVD, age a t diagnosis o r b o th . (a) Kaplan-Meier (KM) [36] curves 
fo r the 247 patients w ith  TCGA annotations in the initial set o f 251 patients, classified by copy numbers in the second probelet, which is com puted by 
GSVD fo r the 251 patients, show a median survival tim e difference o f * 1 6  months, w ith  the corresponding log-rank test P-value < 1 0 _3. The 
univariate Cox [37] proportional hazard ratio is 2.3, w ith  a P-value <  10_2 (Table S1), meaning that high relative copy numbers in the second probelet 
confer more than tw ice the hazard o f low numbers. The P-values are calculated w ith ou t adjusting fo r m ultip le  comparisons [38]. (b) Survival analyses 
o fth e  247 patients classified by age, i.e., > 5 0  o r < 5 0  years old at diagnosis, show that the prognostic contribu tion  o fage , w ith  a KM median survival
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tim e difference o f * 1 1  m onths and a univariate Cox hazard ratio o f 2, is comparable to  that o f GSVD. (c) Survival analyses o f the 247 patients 
classified by both GSVD and age, show sim ilar m ultivaria te Cox hazard ratios, o f 1.8 and 1.7, that do not d iffer significantly from  the corresponding 
univariate hazard ratios, o f 2.3 and 2, respectively. This means that GSVD and age are independent prognostic predictors. W ith a KM median survival 
tim e difference o f *  22 months, GSVD and age com bined make a better predictor than age alone. (d) Survival analyses o f the 334 patients w ith  TCGA 
annotations and a GSVD classification in the inclusive confirm ation set o f 344 patients, classified by copy numbers in the second probelet, which is 
com puted by GSVD fo r the 344 patients, show a KM median survival tim e difference o f *  16 m onths and a univariate hazard ratio o f2.4 , and confirm 
the survival analyses o f the initial set o f 251 patients. (e) Survival analyses o f the 334 patients classified by age confirm  that the prognostic 
contribu tion  o f age, w ith  a KM median survival tim e difference o f *  10 months and a univariate hazard ratio o f 2, is comparable to  that o f GSVD. (f) 
Survival analyses o f the 334 patients classified by both GSVD and age, show similar multivariate Cox hazard ratios, o f 1.9 and 1.8, that do not differ 
s ign ifican tly from  the corresponding univariate hazard ratios, and a KM median survival tim e difference o f * 2 2  m onths ,w ith  the corresponding log- 
rank test P-value <  10_5. This confirms that the prognostic contribu tion  o f GSVD is independent o f age, and that combined w ith  age, GSVD makes a 
bette r predictor than age alone. (g) Survival analyses o f the 183 patients w ith  a GSVD classification in the independent validation set o f 184 patients, 
classified by correlations o f each patient's GBM profile w ith  the second tum or arraylet, which is com puted by GSVD fo r the 251 patients, show a KM 
median survival tim e difference o f *  12 months and a univariate hazard ratio o f2.9 , and validate the survival analyses o fth e  initial set o f251 patients. 
(h) Survival analyses o f the 183 patients classified by age validate that the prognostic contribu tion  o f age is comparable to  that o f GSVD. (i) Survival 
analyses o f the 183 patients classified by both GSVD and age, show similar m ultivaria te Cox hazard ratios, o f 2 and 2.2, and a KM median survival time 
difference o f * 4 1  months, w ith  the corresponding log-rank test P-value < 1 0 _5. This validates that the prognostic contribu tion  o f GSVD is 
independent o f age, and that com bined w ith  age, GSVD makes a better predictor than age alone, also fo r patients w ith  measured GBM aCGH profiles 
in the absence o f matched normal profiles. 
doi:10.1371/journal.pone.0030098.g003
*  7 months longer than that for the rem aining chem otherapy 
patients in each case (Figure S15 in Appendix S1). This suggests 
that drug-targeting the kinase that TLK2 encodes an d /o r  the 
methyltransferase-like proteins that M E T T L 2 A /B  encode may 
affect not only the pathogenesis but also the prognosis o fG B M  as 
well as the patient’s response to chem otherapy.
Taken together, we find that the global pattern  provides a better 
prognostic predictor than  the chromosome numbers or any one 
focal CNA that it identifies. This suggests that the GBM survival 
phenotype is an outcome o f its global genotype.
Despite the recent genome-scale molecular profiling efforts, age 
a t diagnosis remains the best prognostic predictor for GBM in 
clinical use. The K M  m edian survival time difference between the 
patients > 5 0  or < 5 0  years old a t diagnosis is * 1 1  months, 
approximately two thirds o f the *  16 months difference observed 
for the global pattern, with the log-rank test P-value < 1 0 _4 
(Figure 3b). The univariate Cox proportional hazard ratio we 
calculate for age is 2, i.e., similar to that for the global pattern. 
Taken together, the prognostic contribution of the global pattern  is 
comparable to that o f age. Similarly we find that the prognostic 
contribution o f the global pattern  is comparable to that of 
chem otherapy (Figure S16a in Appendix S1).
To examine whether the weight o f the global pattern  in a 
patient’s GBM aC G H  profile is correlated with the patien t’s age at 
diagnosis, we classify the patients into four groups, with prognosis 
o f longer-term survival according to both, only one or neither of 
the classifications (Figure 3c). The K M  curves for these four groups 
are significantly different, with the log-rank test P-value <  10_4. 
W ithin each age group, the subgroup o f patients with low relative 
copy num bers in the second probelet consistently exhibits longer 
survival than  the rem aining patients. The m edian survival time of 
the 16 patients <  50 years old at diagnosis with low copy numbers 
in the second probelet is * 3 4  months, almost three times longer 
than  the *  12 months m edian survival time o f the patients >  50 
years old a t diagnosis with high numbers in the second probelet. 
T he multivariate Cox proportional hazard ratios for the global 
pattern  and age are 1.8 and 1.7, respectively, with both 
corresponding P-values < 3  x  10_2. These ratios are similar, 
m eaning that both  a high weight o f the global pattern  in a patien t’s 
GBM  aC G H  profile and an age > 5 0  years old at diagnosis confer 
similar relative hazard. These ratios also do not differ significantly 
from the univariate ratios of 2.3 and 2 for the global pattern  and 
age, respectively. Taken together, the prognostic contribution of 
the global pattern  is not only comparable to that ofage, bu t is also 
independent of age. Com bined with age, the global pattern  makes
a better predictor than age alone. Similarly, we find that the global 
pattern  is independent o f chem otherapy (Figure S16b in Appendix 
S1).
T o  confirm the global pattern, we use GSVD to compare 
m atched profiles o f a larger, more recent, set o f 344 TC G A  
patients, that is inclusive o f the initial set o f 251 patients [15]. 
Agilent H um an aC G H  244A-measured 458 tum or and 459 
norm al profiles were selected, corresponding to the inclusive 
confirmation set of N  = 344 patients (Dataset S4). The profiles, 
centered at their autosomal median copy numbers, are organized 
in one tum or and one norm al dataset, o f M i =200,139 and 
M 2 = 198,342 probes, respectively. W ithin each set, the medians 
of profiles o f samples from the same patient are taken after 
estimating missing data by using SVD. W e find that the significant 
probelets and corresponding tum or and norm al arraylets, as well 
as their interpretations, are robust to the increase from 251 
patients in the initial set to 344 patients in the inclusive 
confirmation set, and  the accompanying decreases in tum or and 
norm al probes, respectively.
The second tum or arraylet com puted by GSVD for the 344 
patients o f the inclusive confirm ation set correlates with that o f the 
initial set, with the correlation *  0.99. T o  classify the patients 
according to the copy numbers listed in the corresponding second 
probelet o f the inclusive confirm ation set, the classification cutoff 
+  0.02 of the initial set of 251 patients is scaled by the norm  of the 
copy numbers listed for these patients, resulting in the cutoff 
+  0.017. Only four o f the 251 patients in the initial set, i.e.,
*  1.5%, with copy numbers that are near the classification cutoffs 
of both  sets, change classification. O f the 344 patients, we find that 
315 patients, 309 with T C G A  annotations, display high (>0.017) 
and 27, i.e., * 8 % , display low, approximately zero, relative copy 
numbers in the second probelet. Only two patients, one missing 
T C G A  annotations, rem ain unclassified with large negative 
( < —0.017) copy numbers in the second probelet. Survival 
analyses o f the inclusive confirm ation set of 344 patients give 
qualitatively the same results as these of the initial set o f 251 
patients. These analyses confirm that a negligible weight of the 
global pattern, which is described by the second tum or arraylet, 
i.e., a low copy num ber in the second probelet, is indicative of a 
significantly longer survival time (Figure 3d). Survival analysis of 
only the chem otherapy patients in the inclusive confirm ation set 
classified by GSVD gives similar results (Figure S10b in Appendix 
S1). These analyses confirm that the prognostic contribution ofthe  
global pattern  is comparable to that o f age (Figure 3e) and is 
independent of age (Figure 3 f ). Similarly, we confirm that the
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global pattern  is independent o f chem otherapy (Figures S16 c and 
d in Appendix S1).
To validate the prognostic contribution o f the global pattern, we 
classify GBM profiles o f an  independent set o f 184 TCG A  
patients, that is mutually exclusive o f the initial set o f 251 patients. 
Agilent H um an aC G H  244A-measured 280 tum or profiles were 
selected, corresponding to the independent validation set o f 184 
patients with available T C G A  status annotations (Dataset S5). 
Each profile lists relative copy numbers in more than 97.5% ofthe  
206,820 autosom al probes am ong the M i =212,696 probes that 
define the second tum or arraylet com puted by GSVD for the 251 
patients of the initial set. M edians o f profiles o f samples from the 
same patient are taken. T o  classify the 184 patients according to 
the correlations o f their GBM profiles with the second tum or 
arraylet of the initial set, the classification cutoff of the initial set of 
251 patients is scaled by the norm  o f the correlations calculated for 
these patients, resulting in the cutoff +  0.15. For the profiles o f 162 
patients we calculate high (> 0.15) and for 21, i.e., * 1 1 % , low, 
approximately zero, correlation with the second tum or arraylet. 
O ne patient remains unclassified with a large negative (<  —0.15) 
correlation.
We find that survival analyses o f the independent validation set 
o f 184 patients give qualitatively the same results as these o f the 
initial set o f 251 patients and the inclusive confirm ation set o f 344 
patients (Figures 2 g -i  and Figures S10c, and  S16 e and f  in 
Appendix S1). These analyses validate the prognostic contribution 
o f the global pattern, which is com puted by GSVD of patient- 
m atched tum or and norm al aC G H  profiles, also for patients with 
measured GBM  aC G H  profiles in the absence of m atched normal 
profiles.
Discussion
Previously, we showed that the GSVD provides a m athematical 
framework for sequence-independent comparative modeling of 
D NA m icroarray data from two organisms, where the m athem at­
ical variables and operations represent experimental or biological 
reality [12,29]. The variables, subspaces o f significant patterns that 
are com m on to both or exclusive to either one of the datasets, 
correlate with cellular programs that are conserved in both  or 
unique to either one of the organisms, respectively. The operation 
o f reconstruction in the subspaces common to both  datasets 
outlines the biological similarity in the regulation of the cellular 
programs that are conserved across the species. Reconstruction in 
the com m on and  exclusive subspaces of either dataset outlines the 
differential regulation o f the conserved relative to the unique 
programs in the corresponding organism. Recent experimental 
results [40] verify a computationally predicted genome-wide mode 
o f regulation [41,42], and demonstrate that GSVD modeling of 
DNA m icroarray data can be used to correctly predict previously 
unknown cellular mechanisms.
Recently, we mathematically defined a higher-order GSVD 
(HO GSVD) for more than two large-scale matrices with different 
row dimensions and  the same column dimension [13]. W e proved 
that this novel H O  GSVD extends to higher orders almost all of 
the m athem atical properties of the GSVD. W e showed, com par­
ing global m RNA expression from the three disparate organisms S. 
pombe, S. cerevisiae and hum an, that the H O  GSVD provides a 
sequence-independent comparative framework for more than two 
genomic datasets, where the variables and operations represent 
experimental or biological reality. T he approximately common 
H O  GSVD subspace represents biological similarity am ong the 
organisms. Simultaneous reconstruction in the com m on subspace
removes the experimental artifacts, which are dissimilar, from the 
datasets.
W e now show that also in probe-independent comparison of 
aC G H  data from patient-m atched tum or and norm al samples, the 
m athem atical variables o f the GSVD, i.e., shared probelets and 
the corresponding tum or- and normal-specific arraylets, represent 
experimental or biological reality. Probelets that are m athem at­
ically significant in both datasets, correspond to norm al arraylets 
representing copy-number variations (CNVs) in the norm al 
hum an genome that are conserved in the tum or genome (e.g., 
female-specific X  chromosome amplification) and are represented 
by the corresponding tum or arraylets. Probelets that are 
mathematically significant in the norm al but not the tum or 
dataset represent experimental variations that exclusively affect the 
norm al dataset. Similarly, some probelets that are mathematically 
significant in the tum or but not the norm al dataset represent 
experimental variations that exclusively affect the tum or dataset.
W e find that the mathematically second most tumor-exclusive 
probelet, which is also the mathematically most significant 
probelet in the tum or dataset, is statistically correlated, possibly 
biologically coordinated with GBM patients’ survival and response 
to chem otherapy. The corresponding tum or arraylet describes a 
global pattern  of tumor-exclusive co-occurring CNAs, including 
most known GBM-associated changes in chromosome numbers 
and focal CNAs, as well as several previously unreported CNAs, 
including the biochemically putative drug target-encoding TLK2
[14]. W e find that a negligible weight of the second tum or arraylet 
in a patient’s GBM aC G H  profile, mathematically defined by 
either the corresponding copy num ber in the second probelet, or 
by the correlation o f the GBM profile with the second arraylet, is 
indicative o f a significantly longer GBM survival time. This GSVD 
comparative modeling o f aC G H  data from patient-m atched tumor 
and norm al samples, therefore, draws a m athem atical analogy 
between the prediction o f cellular modes of regulation and  the 
prognosis o f cancers.
W e confirm our results with GSVD com parison of matched 
profiles o f a larger set o f T C G A  patients, inclusive of the initial set. 
We validate the prognostic contribution o f the pattern  with GSVD 
classification o f the GBM profiles o f a set o f patients that is 
independent o f both  the initial set and the inclusive confirm ation 
set [15].
Additional possible applications o f the GSVD (and also the H O  
GSVD) in personalized medicine include comparisons of multiple 
patient-m atched datasets, each corresponding to either (i) a set of 
large-scale molecular biological profiles (such as DNA copy 
numbers) acquired by a high-throughput technology (such as 
DNA microarrays) from the same tissue type (such as tum or or 
normal); or (ii) a set o f biomedical images or signals; or (iii) a set of 
anatom ical or clinical pathology test results or phenotypical 
observations (such as age). GSVD comparisons can uncover the 
relations and  possibly even causal coordinations between these 
different recorded aspects of the same medical phenom enon. 
GSVD comparisons can be used to determine a single patient’s 
medical status in relation to all the other patients in the set, and 
inform the patien t’s diagnosis, prognosis and  treatm ent.
Supporting Information
Appendix S1 Figures S1, S2, S3, S4, S5, S6, S7, S8, S9, 
S10, S11, S12, S13, S14, S15, S16 and Tables S1 and S2. A
PDF form at file, readable by Adobe Acrobat Reader.
(PDF)
Mathematica Notebook S1 Generalized singular value 
decom position (GSVD) o f the TCG A patient-matched
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tum or and norm al aC G H  profiles. A M athem atica 8.0.1 
code file, executable by M athem atica 8.0.1 and  readable by 
M athem atica Player, freely available a t http ://w w w .w olfram . 
com /products/p layer/.
(NB)
Mathematica Notebook S2 Generalized singular value 
decom position (GSVD) o f the TC G A patient-matched 
tum or and norm al aC G H  profiles. A PD F form at file, 
readable by Adobe Acrobat Reader.
(PDF)
Dataset S1 Initial set o f  251 patients. A tab-delimited text 
form at file, readable by both M athem atica and Microsoft Excel, 
reproducing T he  C ancer Genom e Atlas (TCGA) [4] annotations 
o f the initial set o f 251 patients and the corresponding norm al and 
tum or samples. T h e  tum or and norm al profiles of the initial set of 
251 patients, in tab-delimited text form at files, tabulating log2 
relative copy num ber variation across 212,696 and 211,227 tumor 
and  norm al probes, respectively, are available a t h ttp ://w w w . 
alterlab.org/G BM _prognosis/.
(TXT)
Dataset S2 Segments o f  the significant tum or and 
norm al arraylets, com puted by GSVD for the initial set 
o f  251 patients. A tab-delimited text form at file, readable by 
bo th  M athem atica and  Microsoft Excel, tabulating segments 
identified by circular binary segmentation (CBS) [20,21].
(TXT)
Dataset S3 Segments o f  the second tum or arraylet, 
com puted by GSVD for the initial set o f  251 patients. A
tab-delimited text form at file, readable by both M athem atica and 
Microsoft Excel, tabulating, for each o f the 130 CBS segments of 
the second tum or arraylet, the segment’s coordinates, the CBS P- 
value, and the log-rank test P-value corresponding to the Kaplan-
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Supplem en tary  Tables and  Figures
Cox Proportional 
Hazard Model Predictor
Initial Set Inclusive Confirmation Set Independent Validation Set
Hazard Ratio P-value Hazard Ratio P-value Hazard Ratio P-value
Univariate GSVD 2.3 1.3x10-3 2.4 6.5x10-4 2.9 3.6x10-4
Age 2.0 7.9x10-5 2.0 4.3x 10-b 2.7 1.7x10-b
Multivariate GSVD 1.8 2.2x 10-2 1.9 1.2x 10-2 2.0 2.2x 10-2
Age 1.7 2.0x10-3 1.8 1.0x10-4 2.2 2.0x10-4
Table S1. Cox proportional hazard models of the three sets of patients classified by GSVD, age at 
diagnosis or both. In each set of patients, the multivariate Cox proportional hazard ratios [37] for GSVD and age 
are similar and do not differ significantly from the corresponding univariate hazard ratios. This means that GSVD 
and age are independent prognostic predictors.
Cox Proportional 
Hazard Model Predictor
Initial Set Inclusive Confirmation Set Independent Validation Set
Hazard Ratio P -value Hazard Ratio P-value Hazard Ratio P-value
Univariate GSVD 2.4 1.2x10-3 2.4 6.4x 10-4 2.8 1.3x 10-3
Chemotherapy 2.6 1.5x10-8 2.7 6.3x10-11 2.2 7.3x10-4
Multivariate GSVD 3.0 5.2x 10-5 3.1 2.5x 10-5 3.3 2.3x 10-4
Chemotherapy 3.1 7.9x10-11 3.2 1.9x10-13 2.7 3.0x10-5
Table S2. Cox proportional hazard models of the three sets of patients classified by GSVD, chemother­
apy or both. In each set of patients, the multivariate Cox proportional hazard ratios for GSVD and chemotherapy 
are similar and do not differ significantly from the corresponding univariate hazard ratios. This means that GSVD 
and chemotherapy are independent prognostic predictors. The P-values are calculated without adjusting for multiple 
comparisons [38].
Figure S1. Most significant pro- 
belets in the tumor and normal 
datasets. (o) Bar chart of the ten 
most significant probelets in the tu­
mor dataset in terms of the general­
ized fraction that each probelet cap­
tures in this dataset (Equation 2), 
showing that the two most tumor- 
exclusive probelets, i.e., the first pro- 
belet (Figure S2) and the second pro- 
belet (Figure 2 o-c), with angular 
distances >2n/9, are also the two 
most significant probelets in the tu­
mor dataset, with ~11% and 22% of 
the information in this dataset, re­
spectively. The “generalized normal­
ized Shannon entropy” (Equation 3) 
of the tumor dataset is di=0.73.
(b) Bar chart of the generalized fractions of the ten most significant probelets in the normal dataset, showing that the 
five most normal-exclusive probelets, the 247th to 251st probelets (Figures S3-S7), with angular distances < —n/6, are 
among the seven most significant probelets in the normal dataset, capturing together ~56% of the information in this 
dataset. The 246th probelet (Figure 1 d-f), which is relatively common to the normal and tumor datasets with an 
angular distance > —n/6, is the second most significant probelet in the normal dataset with ~8% of the information. 
The generalized entropy of the normal dataset, ^2=0.59, is smaller than that of the tumor dataset. This means that 
the normal dataset is more redundant and less complex than the tumor dataset.
(a) Tumor Generalized Fraction (b) Normal Generalized Fraction
di = 0.73 d2 = 0.59
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F igu re  S2. T he  first m ost tum or-exc lusive  p ro b e le t an d  co rrespond ing  tu m o r a rra y le t uncov­
ered  by G SV D  of th e  p a tien t-m a tch ed  G B M  an d  norm al aC G H  profiles. (a) Plot of the first tumor 
arraylet describes unsegmented [20,21] chromosomes (black lines), each with copy-number distributions which are 
approximately centered at zero with relatively large, chromosome-invariant widths. The probes are ordered, and their 
copy numbers are colored, according to each probe’s chromosomal location. (b) Plot of the first most tumor-exclusive 
probelet, which is also the second most significant probelet in the tumor dataset (Figure S1a), describes the 
corresponding variation across the patients. The patients are ordered according to each patient’s relative copy 
number in this probelet. These copy numbers significantly correlate with the genomic center where the GBM samples 
were hybridized at, HMS (red), MSKCC (blue) or multiple locations (gray), with the P-values <10-5 (Table 1 and 
Figure S8a). (c) Raster display of the tumor dataset, with relative gain (red), no change (black) and loss (green) 
of DNA copy numbers, shows the correspondence between the GBM profiles and the first probelet and tumor arraylet.
(a) Normal Arraylet 247
Relative
Copy Number (c) Normal Relative DNA Copy Number
F igu re  S3. T he  247th , norm al-exclusive p ro b e le t an d  co rrespond ing  norm al a rray le t uncovered
by G SV D . (a) Plot of the 247th normal arraylet describes copy-number distributions which are approximately 
centered at zero with relatively large, chromosome-invariant widths. The normal probes are ordered, and their copy 
numbers are colored, according to each probe’s chromosomal location. (b) Plot of the 247th probelet describes the 
corresponding variation across the patients. Copy numbers in this probelet correlate with the date of hybridization of 
the normal samples, 7.22.2009 (red), 10.8.2009 (blue) or other (gray), with the P-values <10-3 (Table 1 and Figure 
S8b). (c) Raster display of the normal dataset shows the correspondence between the normal profiles and the 247th 
probelet and normal arraylet.
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(a) Normal Arraylet 248
Copy Number (c) Normal Relative DNA Copy Number
F igu re  S4. T he  248th , norm al-exclusive p ro b e le t and  co rrespond ing  norm al a rray le t uncovered
by G SV D . (a) Plot of the 248th normal arraylet describes copy-number distributions which are approximately 
centered at zero with relatively large, chromosome-invariant widths. (b) Plot of the 248th probelet describes the 
corresponding variation across the patients. Copy numbers in this probelet significantly correlate with the tissue 
batch/hybridization scanner of the normal samples, HMS 8/2331 (red) and other (gray), with the P-values <10-12 
(Table 1 and Figure S8c). (c) Raster display of the normal dataset shows the correspondence between the normal 
profiles and the 248th probelet and normal arraylet.
[a) Normal Arraylet 249
Copy Number (c) Normal Relative DNA Copy Number
F igu re  S5. T he  249th , norm al-exclusive p ro b e le t and  co rrespond ing  norm al a rray le t uncovered
by G SV D . (a) Plot of the 249th normal arraylet describes copy-number distributions which are approximately 
centered at zero with relatively large, chromosome-invariant widths. (b) Plot of the 249th probelet describes the 
corresponding variation across the patients. Copy numbers in this probelet significantly correlate with the tissue 
batch/hybridization scanner of the normal samples, HMS 8/2331 (red) and other (gray), with the P-values <10-12 
(Table 1 and Figure S8d). (c) Raster display of the normal dataset shows the correspondence between the normal 
profiles and the 249th probelet and normal arraylet.
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[a) Normal Arraylet 250
:opy Number (c) Normal Relative DNA Copy Number
Figure S6. The 250th, normal-exclusive probelet and corresponding normal arraylet uncovered
by GSVD. (a) Plot of the 250th normal arraylet describes copy-number distributions which are approximately 
centered at zero with relatively large, chromosome-invariant widths. (b) Plot of the 250th probelet describes the 
corresponding variation across the patients. Copy numbers in this probelet correlate with the date of hybridization of 
the normal samples, 4.18.2007 (red), 7.22.2009 (blue) or other (gray), with the P-values <10-3 (Table 1 and Figure 
S8e). (c) Raster display of the normal dataset shows the correspondence between the normal profiles and the 250th 
probelet and normal arraylet.
(a) Normal Arraylet 251
Copy Number (c) Normal Relative DNA Copy Number
Figure S7. The first most normal-exclusive, i.e., 251st probelet and corresponding normal ar­
raylet uncovered by GSVD. (a) Plot of the 251st normal arraylet describes unsegmented [20,21] chromosomes 
(black lines), each with copy-number distributions which are approximately centered at zero with relatively large, 
chromosome-invariant widths. (b) Plot of the first most normal-exclusive probelet, which is also the most significant 
probelet in the normal dataset (Figure S1b), describes the corresponding variation across the patients. Copy numbers 
in this probelet significantly correlate with the genomic center where the normal samples were hybridized at, HMS 
(red), MSKCC (blue) or multiple locations (gray), with the P-values <10-13 (Table 1 and Figure S8f). (c) Raster 
display of the normal dataset shows the correspondence between the normal profiles and the 251st probelet and 
normal arraylet.
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(a ) P r o b e l e t  1 
P - v a lu e  = 2 . 5  x 1 0 -
(b ) P r o b e l e t  247 
P - v a lu e  = 7 .6  x 10 -4
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F ig u re  S8 (cap tions on p. A-6).
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F ig u re  S9 (cap tions on p. A-6).
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Figure S8 (on p. A -5). Differences in copy numbers among 
the TCG A annotations associated with the significant pro­
belets. Boxplot visualization of the distribution of copy numbers 
of the (a ) first, most tumor-exclusive probelet among the associated 
genomic centers where the GBM samples were hybridized at (Table 1); 
(b) 247th, normal-exclusive probelet among the dates of hybridization 
of the normal samples; (c) 248th, normal-exclusive probelet between 
the associated tissue batches/hybridization scanners of the normal 
samples; (d) 249th, normal-exclusive probelet between the associated 
tissue batches/hybridization scanners of the normal samples; (e) 250th, 
normal-exclusive probelet among the dates of hybridization of the normal 
samples; ( f ) 251st, most normal-exclusive probelet among the associated 
genomic centers where the normal samples were hybridized at. The 
Mann-Whitney-Wilcoxon P-values correspond to the two annotations 
that are associated with largest or smallest relative copy numbers in each 
probelet.
Figure S9 (on p. A -5). Copy-number distributions of the 246th 
probelet and the corresponding 246th normal arraylet and 246th 
tumor arraylet. Boxplot visualization and Mann-Whitney-Wilcoxon 
P-values of the distribution of copy numbers of the (a) 246th probelet, 
which is approximately common to both the normal and tumor datasets, 
and is the second most significant in the normal dataset (Figure S1b), 
between the gender annotations (Table 1); (b) 246th normal arraylet 
between the autosomal and X chromosome normal probes; (c) 246th 
tumor arraylet between the autosomal and X chromosome tumor probes.
(a ) P r o b e l e t  2 ( C o e f f .  
P - v a lu e  = 8 .5  x 10-3
£ E
(b ) P r o b e l e t  2 ( C o e f f .  
P - v a lu e  = 5 .4  x 10-3
( c )  A r r a y l e t  2 (C o r r . )  
P - v a lu e  = 5 . 3  x 10-3
Survival Time (Months)
Figure S10. Kaplan-Meier
(KM) survival analyses of only 
the chemotherapy patients from 
the three sets classified by GSVD.
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IDH1 M u ta t io n  
P - v a lu e  = 1 .2  x 10°
IDH1 M u ta t io n  
P - v a lu e  = 1 x 10-1
F ig u re  S11 (left). K M  
surv ival analysis o f th e  
in itia l se t o f 251 p a tien ts  
classified by a  m u ta tio n  
in th e  gene IDH1.
F ig u re  S12 (rig h t) . K M  
surv ival analysis o f only 
th e  ch em o th erap y  pa­
tie n ts  in  th e  in itia l se t, 
classified by a  m u ta tio n  
in IDH1.
Survival Time (Months) Survival Time (Months)
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F ig u re  S13. K M  surv ival analyses o f th e  in itia l se t o f 251 p a tie n ts  classified by  G B M -associa ted  
chrom osom e nu m b er changes. (a) Analysis of the 247 patients with TCGA annotations in the initial set of 
251 patients, classified by number changes in chromosome 10, shows almost overlapping Kaplan-Meier (KM) [36] 
curves with a KM median survival time difference of ~2 months, and a corresponding log-rank test P-value ~10-1 , 
meaning that chromosome 10 loss, frequently observed in GBM, is a poor predictor of GBM patients’ survival. 
(b) KM survival analysis of the 247 patients classified by number changes in chromosome 7 shows almost overlapping 
KM curves with a KM median survival time difference of <one month, and a corresponding log-rank test P-value 
>5x 10-1 , meaning that chromosome 7 gain is a poor predictor of GBM survival. (c) KM survival analysis of the 247 
patients classified by number changes in chromosome 9p shows a KM median survival time difference of ~3 months, 
and a log-rank test P-value >10-1 , meaning that chromosome 9p loss is a poor predictor of GBM survival.
F ig u re  S14 (on p. A -8). K M  surv ival analyses o f th e  in itia l se t o f 251 p a tie n ts  classified by copy num ber 
changes in  se lec ted  segm en ts con ta in ing  G B M -associa ted  genes o r genes p rev iously  unrecognized  in 
G BM . In the KM survival analyses of the groups of patients with either a CNA or no CNA in either one of the 
130 segments identified by the global pattern, i.e., the second tumor-exclusive arraylet (Dataset S3), log-rank test 
P-values < 5x10-2 are calculated for only 12 of the classifications. Of these, only six correspond to a KM median 
survival time difference that is >5 months, approximately a third of the ~16 months difference observed for the GSVD 
classification. One of these segments contains the genes TLK2 and METTL2A, previously unrecognized in GBM. The 
KM median survival time we calculate for the 56 patients with TLK2 amplification is ~5 months longer than that for 
the remaining patients. This suggests that drug-targeting the kinase and/or the methyltransferase-like protein that 
TLK2 and METTL2A encode, respectively, may affect not only the pathogenesis but also the prognosis of GBM.
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Figure S15. K M  survival analyses of only the chemotherapy patients in the initial set of 251 patients classified by copy number changes 
in selected segments.
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Figure S16. Survival analyses (a ) C h em oth era p y  (b ;
of the patients from the three P - v a lu e  = 4 . 3 x 10-9
sets classified by chemotherapy H a zard  R a t i o  = 2 .6
alone or GSVD and chemother­
apy both. (a) KM and Cox survival £ 
analyses of the 236 patients with -S 
TCGA chemotherapy annotations in £ £ 
the initial set of 251 patients, classi- .= 3 
fied by chemotherapy, show that lack 
of chemotherapy, with a KM me- = 
dian survival time difference of ~10 o +- 
months and a univariate hazard ra- § 8 
tio of 2.6 (Table S2), confers more |  
than twice the hazard of chemother- £ 
apy. (b) Survival analyses of the 
236 patients classified by both GSVD 
and chemotherapy, show similar mul­
tivariate Cox hazard ratios, of 3 
and 3.1, respectively. This means 
that GSVD and chemotherapy are 
independent prognostic predictors. $
W ith a KM median survival time g <= 
difference of ^30 months, GSVD £ |  
and chemotherapy combined make a 
better predictor than chemotherapy > § 
alone. (c) Survival analyses of the £ g 
317 patients with TCGA chemother- “ g 
apy annotations in the inclusive con- ° £ 
firmation set of 344 patients, classi- ■_§ 
fied by chemotherapy, show a KM §  ^
median survival time difference of 8 
~11 months and a univariate haz­
ard ratio of 2.7, and confirm the sur­
vival analyses of the initial set of 251 
patients. (d) Survival analyses of 
the 317 patients classified by both 
GSVD and chemotherapy show simi- et  
lar multivariate Cox hazard ratios, of 3 “
3.1 and 3.2, and a KM median sur- .§ $ 
vival time difference of ~30 months, £ I 
with the corresponding log-rank test 
P-value <10-17. This confirms that 
the prognostic contribution of GSVD 
is independent of chemotherapy, and 
that combined with chemotherapy,
GSVD makes a better predictor than 
chemotherapy alone. (e) Survival 
analyses of the 154 patients with 
TCGA chemotherapy annotations in
the independent validation set of 184 Survival Time (Mont hs;
patients, classified by chemotherapy,
show a KM median survival time difference of ~11 months and a univariate hazard ratio of 2.2, and validate the 
survival analyses of the initial set of 251 patients. ( f ) Survival analyses of the 154 patients classified by both GSVD 
and chemotherapy, show similar multivariate Cox hazard ratios, of 3.3 and 2.7, and a KM median survival time 
difference of ~43 months. This validates that the prognostic contribution of GSVD is independent of chemotherapy, 
and that combined with chemotherapy, GSVD makes a better predictor than chemotherapy alone, also for patients 
with measured GBM aCGH profiles in the absence of matched normal profiles.
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